# A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance

> **NCT07321015** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 72 (estimated)

## Conditions studied

- Platinum-sensitive
- TNBC, Triple Negative Breast Cancer
- BRCA1/2 Mutation or Not

## Interventions

- **DRUG:** Fluzoparib Monotherapy

## Key facts

- **NCT ID:** NCT07321015
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-20
- **Primary completion:** 2027-11-30
- **Final completion:** 2027-11-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07321015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07321015, "A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07321015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*